AI-Enhanced Clinical Decision Support and Patient Workflow Solution for Stroke Cleared by FDA

RapidAI (Menlo Park, California), a developer of neurovascular and vascular artificial intelligence (AI)–enhanced clinical decision support and patient workflow solutions, announced it has received FDA 510(k) clearance for Rapid NCCT Stroke.

According to the company, Rapid NCCT Stroke uses AI to analyze noncontrast CT (NCCT) images to detect suspected intracranial hemorrhage and large vessel occlusion of the distal internal carotid artery and middle cerebral artery. The fully automated system then delivers triage and prioritization notifications through picture archiving and communication systems, email, and the Rapid mobile app.

Because NCCT imaging is readily available and is the initial imaging modality used for stroke and trauma patients, care teams can make time-sensitive workflow and transfer decisions faster. For hospitals that do advanced imaging, Rapid NCCT Stroke may significantly reduce the time between CT and CTA scans, stated RapidAI.

Rapid NCCT Stroke is an addition to the RapidAI suite of NC-based solutions for stroke and trauma care.

Neurointerventional news coverage produced in conjunction with Endovascular Today.